141.12
+0.115(+0.08%)
Currency In USD
| Previous Close | 141 |
| Open | 140.49 |
| Day High | 142.39 |
| Day Low | 140.05 |
| 52-Week High | 252.17 |
| 52-Week Low | 140.05 |
| Volume | 491,042 |
| Average Volume | 1.51M |
| Market Cap | 20.56B |
| PE | 12.76 |
| EPS | 11.06 |
| Moving Average 50 Days | 157.29 |
| Moving Average 200 Days | 196.09 |
| Change | 0.12 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $399.72 as of January 16, 2025 at a share price of $141. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $492.77 as of January 16, 2025 at a share price of $141.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
GlobeNewswire Inc.
Jan 14, 2025 12:05 AM GMT
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquar
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
GlobeNewswire Inc.
Nov 19, 2024 6:00 AM GMT
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multipl
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
GlobeNewswire Inc.
Nov 14, 2024 4:23 PM GMT
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”